Davidson Kempner Capital Management Lp decreased Neurocrine Biosciences Inc (NBIX) stake by 32.77% reported in 2017Q4 SEC filing. Davidson Kempner Capital Management Lp sold 39,100 shares as Neurocrine Biosciences Inc (NBIX)’s stock rose 13.16%. The Davidson Kempner Capital Management Lp holds 80,200 shares with $6.22M value, down from 119,300 last quarter. Neurocrine Biosciences Inc now has $7.14B valuation. The stock increased 1.56% or $1.22 during the last trading session, reaching $79.4. About 600,025 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 91.92% since April 22, 2017 and is uptrending. It has outperformed by 80.37% the S&P500.
Cubic Corp (CUB) investors sentiment decreased to 1.13 in 2017 Q4. It’s down -0.71, from 1.84 in 2017Q3. The ratio worsened, as 77 investment managers increased or started new positions, while 68 sold and trimmed stakes in Cubic Corp. The investment managers in our database reported: 23.66 million shares, down from 24.06 million shares in 2017Q3. Also, the number of investment managers holding Cubic Corp in top ten positions was flat from 0 to 0 for the same number . Sold All: 16 Reduced: 52 Increased: 49 New Position: 28.
Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on May, 8. They expect $-0.32 EPS, up 64.44% or $0.58 from last year’s $-0.9 per share. After $0.07 actual EPS reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -557.14% negative EPS growth.
Investors sentiment decreased to 1.31 in 2017 Q4. Its down 0.35, from 1.66 in 2017Q3. It worsened, as 18 investors sold NBIX shares while 76 reduced holdings. 58 funds opened positions while 65 raised stakes. 91.25 million shares or 1.56% less from 92.69 million shares in 2017Q3 were reported. Moreover, Dimensional Fund Advsrs Ltd Partnership has 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 191,994 shares. Barclays Pcl invested in 33,139 shares. Rockefeller Fincl accumulated 3,675 shares or 0% of the stock. Earnest Prtn Ltd Liability Com, a Georgia-based fund reported 28 shares. Tudor Corp Et Al, a Connecticut-based fund reported 28,868 shares. 96 were reported by Northwestern Mutual Wealth. Baker Bros Advsr Lp has invested 0.68% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Acadian Asset Management Lc reported 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). 3,962 are owned by World Asset Management Inc. Utah Retirement System accumulated 0.03% or 16,300 shares. Balyasny Asset Mgmt Limited Liability reported 0.09% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Prelude Cap Mngmt Limited Liability Corp owns 0.09% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 14,705 shares. Massachusetts Financial Services Ma stated it has 108,635 shares or 0% of all its holdings. Healthcor Management Limited Partnership has invested 3.85% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Boothbay Fund Mgmt, a New York-based fund reported 4,190 shares.
Davidson Kempner Capital Management Lp increased Uniti Group Inc stake by 340,000 shares to 871,008 valued at $15.49M in 2017Q4. It also upped Servicemaster Global Hldgs I (NYSE:SERV) stake by 275,000 shares and now owns 1.05M shares. Jack In The Box Inc (Call) (NASDAQ:JACK) was raised too.
Since January 2, 2018, it had 0 insider purchases, and 22 insider sales for $29.59 million activity. $138,499 worth of stock was sold by OBrien Christopher Flint on Tuesday, January 16. 3,750 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares with value of $295,820 were sold by GORMAN KEVIN CHARLES. The insider Lloyd-Smith Malcolm sold $1.40 million. The insider BENEVICH ERIC sold $68,174. The insider Gano Kyle sold $128,460. Bozigian Haig P. also sold $128,575 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Tuesday, January 16. $169,997 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by Grigoriadis Dimitri E..
Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 54 analyst reports since August 18, 2015 according to SRatingsIntel. Piper Jaffray maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Thursday, January 25. Piper Jaffray has “Buy” rating and $103.0 target. The stock has “Buy” rating by BMO Capital Markets on Thursday, August 3. Jefferies maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Monday, June 26. Jefferies has “Buy” rating and $6600 target. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Outperform” rating given on Thursday, November 2 by Leerink Swann. Oppenheimer maintained it with “Buy” rating and $85.0 target in Thursday, November 2 report. The firm earned “Buy” rating on Friday, October 20 by BMO Capital Markets. The rating was maintained by Leerink Swann with “Buy” on Tuesday, October 10. The rating was maintained by Oppenheimer on Tuesday, March 13 with “Buy”. On Wednesday, February 14 the stock rating was maintained by JP Morgan with “Overweight”. The company was maintained on Wednesday, March 21 by Oppenheimer.
Rutabaga Capital Management Llc Ma holds 2.46% of its portfolio in Cubic Corporation for 181,578 shares. Granite Investment Partners Llc owns 276,603 shares or 1.03% of their US portfolio. Moreover, Rodgers Brothers Inc. has 0.78% invested in the company for 40,425 shares. The Wisconsin-based Cortina Asset Management Llc has invested 0.69% in the stock. Morgan Dempsey Capital Management Llc, a Wisconsin-based fund reported 28,161 shares.
The stock decreased 1.43% or $0.95 during the last trading session, reaching $65.4. About 114,152 shares traded. Cubic Corporation (CUB) has risen 20.61% since April 22, 2017 and is uptrending. It has outperformed by 9.06% the S&P500.
Analysts await Cubic Corporation (NYSE:CUB) to report earnings on May, 14. They expect $0.17 EPS, up 750.00% or $0.15 from last year’s $0.02 per share. CUB’s profit will be $4.63 million for 96.18 P/E if the $0.17 EPS becomes a reality. After $-0.01 actual EPS reported by Cubic Corporation for the previous quarter, Wall Street now forecasts -1,800.00% EPS growth.